Allogene Therapeutics, Inc. cash flow statement

In fiscal 2025, Allogene Therapeutics, Inc.'s operations generated −$149m of cash; it spent $386,000 on capital projects, leaving free cash flow of −$150m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Allogene Therapeutics, Inc.: cash flow statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−137	−115	−185	−221	−238	−200	−149
Depreciation and amortisation	5	7	11	14	14	14	12
Stock-based pay	46	65	81	84	66	52	38
Capital spending	51	66	21	5	2	1	0
Free cash flow	−188	−181	−206	−226	−239	−201	−150
Free cash flow after stock pay	−234	−246	−287	−309	−305	−253	−187
Shares issued	0	596	0	0	91	—	—

US$ millions unless shown otherwise. Fiscal quarters.

Allogene Therapeutics, Inc.: cash flow statement, quarterly
Quarter	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q2Jun 2026
Cash from operations	−64	−44	−37	−53	−39	−30	−28	−32
Depreciation and amortisation	4	3	3	3	3	3	3	3
Stock-based pay	14	13	13	12	9	9	8	12
Capital spending	0	0	0	0	0	0	0	0
Free cash flow	−64	−45	−37	−53	−39	−30	−28	−32
Free cash flow after stock pay	−77	−58	−50	−65	−48	−39	−36	−45
Shares issued	—	—	—	10	—	—	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Allogene Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Allogene Therapeutics, Inc.